

REMARKS

Status

The Office Action indicates that Claims 1-7 are being considered and Claims 8-14 and 24-43 are withdrawn from consideration. Applicant respectfully notes that Claims 24, 28, 32, 36 and 40 belong to the elected group as they are directed to a pharmaceutical composition of a compound of Claim 2, 3, 4, 5, or 6. Therefore, pending claims are Claims 1-7, 24, 28, 32, 36 and 40. Support for the amendments can be found in the original claims and throughout the specification. No new matter will be added upon entry of this amendment.

Discussion


The indication of rejoining Group I and Group IV is acknowledged with appreciation.

Claims have been amended to obviate the rejections under 35 U.S.C. §112, 1st paragraph. Withdrawal of the rejections is respectfully requested.

In view of the foregoing, Applicants submit that the application is now in condition for allowance. Early notification of such action is earnestly solicited. If the Examiner has any questions or believes further discussion will aid examination and advance prosecution of the application, a telephone call to the undersigned is invited.

Respectfully submitted,

Date: September 28, 2005



Jing G. Sun, Ph.D.
Agent for Applicants
Registration No. 45,914
Telephone No. (609) 252-3791
Facsimile No. (609) 252-4526

Please forward all future correspondence relating to this application to:

Stephen B. Davis
Patent Department
Bristol-Myers Squibb Company
P.O. Box 4000
Princeton, NJ 08543-4000